Vaccination against a hit-and-run viral cancer

Stevenson, Philip G., May, Janet S., Connor, Viv and Efstathiou, Stacey (2010) Vaccination against a hit-and-run viral cancer. Journal of General Virology, 91 9: 2176-2185. doi:10.1099/vir.0.023507-0


Author Stevenson, Philip G.
May, Janet S.
Connor, Viv
Efstathiou, Stacey
Title Vaccination against a hit-and-run viral cancer
Journal name Journal of General Virology   Check publisher's open access policy
ISSN 0022-1317
1465-2099
Publication date 2010
Year available 2010
Sub-type Article (original research)
DOI 10.1099/vir.0.023507-0
Open Access Status
Volume 91
Issue 9
Start page 2176
End page 2185
Total pages 10
Place of publication Reading, Berks, United Kingdom
Publisher Society for General Microbiology
Collection year 2011
Language eng
Subject 2406 Virology
Abstract Cancers with viral aetiologies can potentially be prevented by antiviral vaccines. Therefore, it is important to understand how viral infections and cancers might be linked. Some cancers frequently carry gammaherpesvirus genomes. However, they generally express the same viral genes as non-transformed cells, and differ mainly in also carrying oncogenic host mutations. Infection, therefore, seems to play a triggering or accessory role in disease. The hit-and-run hypothesis proposes that cumulative host mutations can allow viral genomes to be lost entirely, such that cancers remaining virus-positive represent only a fraction of those to which infection contributes. This would have considerable implications for disease control. However, the hit-and-run hypothesis has so far lacked experimental support. Here, we tested it by using Cre-lox recombination to trigger transforming mutations in virus-infected cells. Thus, 'floxed' oncogene mice were infected with Cre recombinase-positive murid herpesvirus-4 (MuHV-4). The emerging cancers showed the expected genetic changes but, by the time of presentation, almost all lacked viral genomes. Vaccination with a non-persistent MuHV-4 mutant nonetheless conferred complete protection. Equivalent human gammaherpesvirus vaccines could therefore potentially prevent not only viral genome-positive cancers, but possibly also some cancers less suspected of a viral origin because of viral genome loss.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Clinical Medical Virology Centre Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 21 May 2014, 12:37:29 EST by System User on behalf of Clinical Medical Virology Centre